Clinical importance of early intensive medical treatment for improving prognosis in non-ST-elevation acute coronary syndrome;Relevancia clínica del tratamiento farmacológico completo precoz en el pronóstico del síndrome coronario agudo sin elevación del ST

Emergencias

Volumn 23, Issue 6, 2011, Pages 461-467

  Fortuny, Elena ^a   Núñez Gil, Iván J ^a   García Rubira, Juan C ^a   Ruiz Mateos, Borja ^a   Ibáñez, Borja ^a   Gonzalo, Nieves ^a   Vivas, David ^a   Macaya, Carlos ^a   Fernández Ortiz, Antonio ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Drug therapy; Myocardial infarction; Non ST segment elevation acute coronary syndrome; Prognosis; Unstable angina

Indexed keywords

EID: 84055191446     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ferreira-González I, Permanyer-Miralda G, Marrugat J, Heras M, Cuñat J, Civeira E, et al. Estudio MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado). Resultados globales. Rev Esp Cardiol. 2008;61:803-16.
2. Bueno H, Bardají A, Fernández-Ortiz A, Marrugat J, Martí H, Heras M, Investigadores del estudio DESCARTES. Manejo del Síndrome Coronario Agudo Sin Elevación del ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal Español). Rev Esp Cardiol. 2005;58:244-52.
3. Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Brindis RG, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006;166:2027-34.
4. Heras M, Bueno H, Bardají A, Fernández-Ortiz A, Martí H, Marrugat J. Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry. Heart. 2006;92:1571-76.
5. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292:2096-104.
6. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital out-comes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358-63.
7. Tang E, Wong CK, Wilkins G, Herbison P, Williams M, Kay P, et al. Use of evidence-based management for acute coronary syndrome. N Z Med J. 2005;118:U1678.
8. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European society of cardiology. Eur Heart J. 2003;24:28-66.
9. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-40.
10. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-306.
11. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/nonST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:148-304.
12. Aroney CN, Aylward P, Kelly AM, Chew DP, Huang N, Kelly AM, et al. National Heart Foundation of Australia Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. Med J Aust. 2006;184:S1-30.
13. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-16.
14. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA, et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109:745-9.
15. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart. 2010;96:1617-21.
16. Chew DP, Anderson FA, Avezum A, Eagle KA, FitzGerald G, Gore JM, et al; for the GRACE Investigators. Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes. Heart. 2010;96:1201-6.
17. European Society of Cardiology. Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation. Eur Heart J. 2007;28:1598-60.
18. Reiffel JA; American Heart Association; American College of Cardiology. Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clin Cardiol. 2005;28(Supl 1):I28-37.
19. Fuster V. Fine-tuning therapy for acute coronary syndromes. N Engl J Med. 2010;363:976-7.
20. Becker RC, Gibson CM, Jennings LK, Morrow DA. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. Am J Cardiol. 2010;106:S2-3.
21. Saucedo JF. Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. J Thromb Thrombolysis. 2010;30:200-9.
22. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev. 2010 Sep 8;CD002130.
23. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. 1999;354:1757-62.
24. Sun SX, Ye X, Lee KY, Dupclay L Jr, Plauschinat C. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. Clin Ther. 2008;30:2217-27.
25. Anon. The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA. 1981;246:2073-4.
26. Cannon CP, Steinberg BA, Murphy SA Mega JL, Braunwald E. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438-45.
27. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a metaanalysis of randomized controlled trials. Arch Intern Med. 2006;166:1814-21.
28. Núñez-Gil IJ, García-Rubira JC, Luaces M, Vivas D, De Agustín JA, González-Ferrer JJ, et al. Mild heart failure is a mortality marker after a non-ST-segment acute myocardial infarction. A. Eur J Intern Med. 2010;21:439-43.
29. Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A, Ricordeau P, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. H. Arch Cardiovasc Dis. 2010;103:363-75.
30. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319-25.
31. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-87.
32. De Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095-104.
33. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or nonST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable angina. Lancet. 2002;360:743-51.
34. Gaspar A, Ribeiro S, Nabais S, Rocha S, Azevedo P, Pereira MA, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol. 2010;29:1511-20.
35. Duerschmied D, Bode C, Moser M. Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Rev Cardiovasc Ther. 2010;8:1215-29.
36. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122:961-13.
37. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51:1247-54.